

BlueShield. OPIOID DRUGS Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

| Patient Information (required) | | Provider Information (required) | | | | |
|--------------------------------|------------|---------------------------------|------------------------|-------------|------|--|
| Date: | | | Provider Name: | | | |
| Patient Name: | | | Specialty: | NPI: | NPI: | |
| Date of Birth: | Sex: ☐Male | □Female | Office Phone: | Office Fax: | | |
| Street Address: | | | Office Street Address: | | | |
| City: | State: | Zip: | City: | State: | Zip: | |
| Patient ID: | | Physician Signature: | | | | |
| PHYSICIAN COMPLETES | | | | | | |

The CDC's Opioid Guideline Mobile App is designed to help providers with Morphine Milligram Equivalent (MME) calculations when prescribing opioids. The CDC app is available for free download on Google Play for Android devices and in the Apple Store for iOS devices

NOTE: Form must be completed in its **entirety** for processing

| Select Drug: | Brand/Generic: | Drug Strength: | Dosing Directions: | |
|---------------------------------|-----------------|-------------------------|--------------------|--|
| EXTENDED RELEASE (ER) OPIOIDS | | | | |
| ☐Buprenorphine film | □Brand □Generic | | | |
| ☐Buprenorphine patch | □Brand □Generic | | | |
| □Fentanyl patch | ☐Brand ☐Generic | | | |
| □Hydrocodone | □Brand □Generic | | | |
| □Hydromorphone | ☐Brand ☐Generic | | | |
| ☐Morphine sulfate | □Brand □Generic | | | |
| ☐Morphine sulfate/naltrexone | □Brand □Generic | | | |
| □Oxycodone | ☐Brand ☐Generic | | | |
| □Oxymorphone | □Brand □Generic | | | |
| □Tapentadol | ☐Brand ☐Generic | | | |
| □Tramadol | ☐Brand ☐Generic | | | |
| | IMMEDIA | TE RELEASE (IR) OPIOIDS | | |
| ☐Butorphanol nasal spray | □Brand □Generic | | | |
| □Codeine tablet | ☐Brand ☐Generic | | | |
| ☐Hydromorphone liquid | ☐Brand ☐Generic | | | |
| ☐Hydromorphone suppository | ☐Brand ☐Generic | | | |
| ☐Hydromorphone tablet | ☐Brand ☐Generic | | | |
| ☐Levorphanol tablet | ☐Brand ☐Generic | | | |
| ☐Meperidine oral solution | ☐Brand ☐Generic | | | |
| ☐Meperidine tablet | ☐Brand ☐Generic | | | |
| ☐Morphine sulfate oral solution | ☐Brand ☐Generic | | | |
| ☐Morphine sulfate suppository | ☐Brand ☐Generic | | | |
| ☐Morphine sulfate tablet | □Brand □Generic | | | |
| ☐Oxycodone capsule | ☐Brand ☐Generic | | | |
| ☐Oxycodone oral solution | □Brand □Generic | | | |
| ☐Oxycodone tablet | ☐Brand ☐Generic | | | |
| ☐Oxymorphone tablet | ☐Brand ☐Generic | | | |
| ☐Pentazocine/naloxone tablet | ☐Brand ☐Generic | | | |
| ☐Tapentadol tablet | ☐Brand ☐Generic | | | |
| ☐Tramadol oral solution | □Brand □Generic | | | |
| ☐Tramadol tablet | ☐Brand ☐Generic | | | |

PLEASE PROCEED TO PAGE 2 FOR ADDITIONAL DRUGS AND QUESTIONS

PAGE 1 of 3



OPIOID DRUGS

DACE 1 DIEVELCIAN COMPLETES

Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan **Prior Approval** P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 **Attn. Clinical Services** Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

| PAGE 2 - PHYSICIAN COMPLETES | | | | | |
|---|--|---|--------------------|--|--|
| Patient Name: | DOB: | Patient ID: R | | | |
| Select Drug: | Brand/Generic: | Drug Strength: | Dosing Directions: | | |
| | | SE (IR) OPIOID COMBO | Domg Directions. | | |
| □Benzhydrocodone/APAP | □Brand □Generic | (III) OTTOID COMIDO | | | |
| □Celecoxib/tramadol tablet | □Brand □Generic | | | | |
| □Codeine/APAP solution | □Brand □Generic | | | | |
| □Codeine/APAP tablet | □Brand □Generic | | | | |
| □Dihydrocodeine/APAP/caffeine tablet | □Brand □Generic | | | | |
| ☐Hydrocodone/APAP elixir | □Brand □Generic | | | | |
| ☐Hydrocodone/APAP solution | □Brand □Generic | | | | |
| ☐Hydrocodone/APAP tablet | ☐Brand ☐Generic | | | | |
| ☐Hydrocodone/ibuprofen tablet | ☐Brand ☐Generic | | | | |
| □Oxycodone/APAP solution | ☐Brand ☐Generic | | | | |
| □Oxycodone/APAP tablet | ☐Brand ☐Generic | | | | |
| □Oxycodone/ASA tablet | ☐Brand ☐Generic | | | | |
| □Oxycodone/ibuprofen tablet | □Brand □Generic | | | | |
| ☐Tramadol/APAP tablet | ☐Brand ☐Generic | | | | |
| | | POWDERS | | | |
| ☐Butorphanol Powder | □Brand □Generic | | | | |
| □Codeine Powder | □Brand □Generic | | | | |
| ☐Hydrocodone Powder | □Brand □Generic | | | | |
| ☐Hydromorphone Powder | □Brand □Generic | | | | |
| □Levorphanol Powder | □Brand □Generic | | | | |
| ☐Meperidine Powder | □Brand □Generic | | | | |
| ☐Morphine Powder | □Brand □Generic | | | | |
| Oxycodone Powder | □Brand □Generic | | | | |
| □Oxymorphone Powder | □Brand □Generic | | | | |
| ***Check www.fepblue.org/formulary to confirm ****Non-covered branded medications must 1. What is the total MME per day of ALL | go through prior authoropioids added togethe | orization and the formulary exception process r for the patient's requested pain regimen? | | | |
| □90 MME per day or less (specify all opioids): | | | | | |
| □Greater than 90 MME per day (specify all opioids): | | | | | |
| *If YES, please specify which: □Pain □Pain | OR treatment associated associated with cance associated with sickle | ed with hospice, palliative, or end-of-life or r or prescribed by a board-certified oncolo | care? □Yes* □No | | |
| 3. Will the patient be using this medication such as Suboxone for opioid addiction? □ Buprenorphine medication for opioid | Yes* (*If YES, plea | | | | |
| Will the patient also be taking Fioricet vaspirin/caffeine/codeine)? □Yes* (*If □Fioricet with codeine (butalbital/APA | YES, please specify which | | | | |
| 5. Is the patient being treated for pain? \Box | Yes □No | | | | |
| 6. Does the prescriber agree to assess the p | | emptoms of serotonin syndrome? □Yes | □No | | |

PLEASE PROCEED TO PAGE 3 FOR ADDITONAL QUESTIONS

PAGE 2 of 3



OPIOID DRUGS Federal Employee Program. PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan **Prior Approval** P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080

Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

| PAGE 3 - PHYSICIAN COMPLETES | | | | |
|--|--|---------------------|--|--|
| Patient Name: | DOB: | Patien | at ID: R | |
| 7. Does the prescriber agree to participate and overdose and discontinue if necessa *Opioid Analgesic REMS Program: ht | ary? □Yes □No | | ND to monitor for abuse, misuse, addiction, | |
| 8. Does the prescriber agree to evaluate th medications? □Yes □No | e patient's response to therap | py before changi | ng dose or adding additional opioid | |
| 9. Will the patient be using this medication lorazepam (Ativan)? □Yes □No | n in combination with alpraz | zolam (Xanax), c | lonazepam (Klonopin), diazepam (Valium), on | |
| 10. Will the patient be using this medication dipotassium (Tranxene)? □Yes □1 | | zepam (Serax), cł | nlordiazepoxide (Librium), or clorazepate | |
| | ontinue to assess the patient f s of misuse/abuse using stand | for the benefits of | wer below: f pain control, for example, by implementing a g (i.e., urine, blood) and evaluating severity or | |
| □ No : Please answer the following que | 1. | | | |
| <u> </u> | including non-opioid analges | | nmediate-release analgesics, been ineffective, No | |
| | se/abuse using standard lab s | | trol, for example, by implementing a care plan ine, blood) and evaluating severity of pain after | |
| | | | ate release or extended release opioid OR have include the requested medication)? □Yes □N | |
| 12. Age 17 or younger : In the last 180 da requested medication)? □Yes □No | • | east a 3-day supp | ly of ANY opioid (this may include the | |
| 13. Age 18 or Older: Has the patient fille days OR is switching from another load | | | mmediate release (IR) opioid in the last 180 | |
| 14. Duragesic (Fentanyl) Patch Request: | Please answer the following | g questions: | | |
| a. Is the requested dosing regimen e | very 48 hours, with a total D | Ouragesic dose le | ss than or equal to 62.5 mcg? □Yes* □No | |
| *If YES, has the patient experie than the one being requested no | | inadequate pain | control at a higher (mg) patch every 72 hours | |
| b. Is the patient using multiple stren | gths? □Yes □No | | | |
| c. How often is the patient changing | this patch? Please select an | iswer below: | | |
| ☐Daily (every 24 hours/QD) | ⊒ Every other day (every 48 | hours/QOD) | □Every 3 days (every 72 hours/Q 72 H) | |
| ☐Other (please specify frequency): | | | | |

PAGE 3 of 3